Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies
MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers
A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2
A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies
Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS)
Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation
Potentiating Antibody Therapy for the Treatment of Cancer
Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients
The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples.
Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines.